The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial of nab-paclitaxel (ABI) and ipilimumab (ipi) in patients with treatment naïve metastatic melanoma.
 
Kaysia Ludford
No Relationships to Disclose
 
Daniel H. Johnson
No Relationships to Disclose
 
Tarin Hennegan
No Relationships to Disclose
 
Stephen K. Gruschkus
No Relationships to Disclose
 
Cara L. Haymaker
Research Funding - Idera; Nektar
 
Chantale Bernatchez
Stock and Other Ownership Interests - Lexicon (I)
Research Funding - EMD Serono; Idera; Iovance Biotherapeutics; MedImmune; Nektar; Pfizer
Patents, Royalties, Other Intellectual Property - Patent pending on BTLA as a marker for better CD8 T cells for adoptive immunotherapy
 
Natalie Jackson
No Relationships to Disclose
 
Patrick Hwu
Stock and Other Ownership Interests - Immatics
Consulting or Advisory Role - Dragonfly Therapeutics; GlaxoSmithKline; Immatics; Sanofi
Research Funding - Genentech (Inst)
 
Adi Diab
Consulting or Advisory Role - Celgene; CureVac; Nektar
Research Funding - Celgene (Inst); Idera (Inst); Nektar (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Nektar